Browsing by Author "Bermejo, Begoña"

Sort by: Order: Results:

  • MicroRNA-33b suppresses epithelial-mesenchymal transition repressing the MYC-EZH2 pathway in HER2+ breast carcinoma
    Pattanayak, Birlipta; Garrido Cano, Iris; Adam-Artigues, Anna; Tormo, Eduardo; Pineda, Begoña; Cabello, Paula; Alonso, Elisa; Bermejo, Begoña; Hernando, Cristina; Martínez, María Teresa; Rovira, Ana; Albanell Mestres, Joan; Rojo, Federico; Burgués, Octavio; Cejalvo, Juan M.; Lluch, Ana; Eroles, Pilar (Frontiers, 2020)
    Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial-mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) ...
  • miR-146a-5p Promotes angiogenesis and confers Trastuzumab Resistance in HER2+ breast cancer
    Cabello, Paula; Torres-Ruiz, Sandra; Adam-Artigues, Anna; Forés-Martos, Jaume; Martínez, María Teresa; Hernando, Cristina; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira, Ana; Burgués, Octavio; Rojo, Federico; Albanell Mestres, Joan; Lluch, Ana; Bermejo, Begoña; Cejalvo, Juan Miguel; Eroles, Pilar (MDPI, 2023)
    Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication ...
  • NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
    Santana-Hernández, Sara; Suárez Olmos, Jesús; Servitja Tormo, Sonia; Berenguer-Molins, Pau; Costa García, Marcel, 1989-; Comerma Blesa, Laura, 1983-; Rea, Anna; Perera Bel, Júlia; Menendez Romero, Silvia; Arpí Llucià, Oriol; Bermejo, Begoña; Martínez, María Teresa; Cejalvo, Juan Miguel; Comino-Méndez, Iñaki; Pascual, Javier; Alba, Emilio; López-Botet, M. (Miguel); Rojo, Federico; Rovira, Ana; Albanell Mestres, Joan; Muntasell i Castellví, Aura, 1972- (BioMed Central, 2024)
    Background: The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural ...
  • Role of SALL4 in HER2+ breast cancer progression: Regulating PI3K/AKT pathway
    Pattanayak, Birlipta; Lameirinhas, Ana; Torres-Ruiz, Sandra; Burgués, Octavio; Rovira, Ana; Martínez, María Teresa; Tapia, Marta; Zazo, Sandra; Albanell Mestres, Joan; Rojo, Federico; Bermejo, Begoña; Eroles, Pilar (MDPI, 2022)
    Treatment for the HER2+ breast cancer subtype is still unsatisfactory, despite breakthroughs in research. The discovery of various new molecular mechanisms of transcription factors may help to make treatment regimens more ...
  • SEOM clinical guidelines in early-stage breast cancer 2015.
    Garcia-Saenz, José Angel; Bermejo, Begoña; Estevez, L. G.; Palomo, A. G.; González-Farré, X.; Margeli, M. E.; Pernas, S.; Servitja Tormo, Sonia; Rodríguez, C. A.; Ciruelos, Eva (Springer, 2015)
    Breast cancer is a major public health problem. Despite remarkable advances in early diagnosis and treatment, one in three women may have metastases since diagnosis. Better understanding of prognostic and predictive factors ...
  • The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
    Tormo, Eduardo; Ballester, Sandra; Adam-Artigues, Anna; Burgués, Octavio; Alonso, Elisa; Bermejo, Begoña; Menendez Romero, Silvia; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico; Lluch, Ana; Eroles, Pilar (Nature Research, 2019)
    The mechanisms of chemotherapy resistance in triple negative breast cancer remain unclear, and so, new molecules which might mediate this resistance could optimize treatment response. Here we analyzed the involvement of ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking